Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 56Squamous Cell Carcinoma of Head and Neck 31Lung Neoplasms 17Head and Neck Neoplasms 17Urinary Bladder Neoplasms 16Oropharyngeal Neoplasms 14Nasopharyngeal Carcinoma 11Parkinson Disease 4, Autosomal Dominant Lewy Body 10Carcinoma 10Small Cell Lung Carcinoma 9Carcinoma, Squamous Cell 9Uterine Cervical Neoplasms 8Pancreatic Neoplasms 8Ovarian Neoplasms 8Carcinoma, Transitional Cell 8Neoplasm Metastasis 7Mouth Neoplasms 7Breast Neoplasms 7Triple Negative Breast Neoplasms 6Recurrence 6Neoplasms 6Melanoma 6Gallbladder Neoplasms 6Esophageal Squamous Cell Carcinoma 6Esophageal Neoplasms 6Colorectal Neoplasms 6Biliary Tract Neoplasms 6Mesothelioma, Malignant 5Medulloblastoma 5Laryngeal Neoplasms 5

Interventions

ruxolitinib 9navitoclax 4Tacrolimus 4Cyclophosphamide 4Whole-Body Irradiation 3Peripheral Blood Stem Cell Transplantation 3Mycophenolic Acid 3venetoclax 2fludarabine phosphate 2fludarabine 2Melphalan 2Busulfan 2veliparib 1selinexor 1pevonedistat 1luspatercept 1letermovir 1itacitinib 1imetelstat 1givinostat hydrochloride 1givinostat 1fedratinib 1elotuzumab 1canakinumab 1avelumab 1Valganciclovir 1Topotecan 1Therapeutics 1Stem Cell Transplantation 1Sirolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Primary Myelofibrosis × Cisplatin × Clear all
NCT04328844 2026-03-30

A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers

iOnctura

Phase 1 Active not recruiting
210 enrolled
DermatologicLymphoidMyeloidOther solid neoplasmThoracic

Uveal Melanoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Melanoma, Mesothelioma, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡